Exploring the intrinsic differences among breast tumor subtypes defined using immunohistochemistry markers based on the decision tree

Exploring the intrinsic differences among breast cancer subtypes is of crucial importance for precise diagnosis and therapeutic decision-making in diseases of high heterogeneity. The subtypes defined with several layers of information are related but not consistent, especially using immunohistochemistry markers and gene expression profiling. Here, we explored the intrinsic differences among the subtypes defined by the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 based on the decision tree. We identified 30 mRNAs and 7 miRNAs differentially expressed along the tree’s branches. The final signature panel contained 30 mRNAs, whose performance was validated using two public datasets based on 3 well-known classifiers. The network and pathway analysis were explored for feature genes, from which key molecules including FOXQ1 and SFRP1 were revealed to be densely connected with other molecules and participate in the validated metabolic pathways. Our study uncovered the differences among the four IHC-defined breast tumor subtypes at the mRNA and miRNA levels, presented a novel signature for breast tumor subtyping, and identified several key molecules potentially driving the heterogeneity of such tumors. The results help us further understand breast tumor heterogeneity, which could be availed in clinics.

[1]  G. Kristiansen,et al.  Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis , 2006, Oncogene.

[2]  H. Gómez,et al.  Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. , 2010, Clinical breast cancer.

[3]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[4]  Bin Zhang,et al.  Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. , 2011, Cancer research.

[5]  Michael J. Birrer,et al.  The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer , 2011, The American journal of surgical pathology.

[6]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[7]  R. Cardiff,et al.  Roles for Nkx3.1 in prostate development and cancer. , 1999, Genes & development.

[8]  G. Plautz,et al.  Abstract 2897: ERBB2 amplicon passenger genes: A novel class of breast cancer antigens , 2014 .

[9]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[10]  N. Marella,et al.  Alterations in replication timing of cancer‐related genes in malignant human breast cancer cells , 2013, Journal of cellular biochemistry.

[11]  G. Mcmahon,et al.  VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.

[12]  Ian O Ellis,et al.  Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.

[13]  Zhonghu Bai,et al.  Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling , 2014, Scientific Reports.

[14]  郑肇葆,et al.  基于Naive Bayes Classifiers的航空影像纹理分类 , 2006 .

[15]  L. Heasley,et al.  Antitumorigenic Effect of Wnt 7a and Fzd 9 in Non-small Cell Lung Cancer Cells Is Mediated through ERK-5-dependent Activation of Peroxisome Proliferator-activated Receptor γ* , 2006, Journal of Biological Chemistry.

[16]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Soonmyung Paik,et al.  Gene expression profiling of breast cancer: a new tumor marker. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Vissers,et al.  Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndrome , 2014, European Journal of Human Genetics.

[19]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Chuan-Yun Li,et al.  KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases , 2011, Nucleic Acids Res..

[21]  Nong Ye,et al.  Naïve Bayes Classifier , 2013 .

[22]  L. Bubendorf,et al.  Role of KCNMA1 in Breast Cancer , 2012, PloS one.

[23]  Shengyuan Yu,et al.  Identification of Differentially Expressed Genes in Pituitary Adenomas by Integrating Analysis of Microarray Data , 2015, International journal of endocrinology.

[24]  S Masood,et al.  Estrogen and progesterone receptors in cytology: A comprehensive review , 1992, Diagnostic cytopathology.

[25]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[26]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[27]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[28]  Zhen-zhou Shen,et al.  Expression of CXCL14 and its anticancer role in breast cancer , 2012, Breast Cancer Research and Treatment.

[29]  Y. M. Kim,et al.  Resveratrol Induces Apoptosis in Chemoresistant Cancer Cells via Modulation of AMPK Signaling Pathway , 2007, Annals of the New York Academy of Sciences.

[30]  John I. McCool,et al.  Probability and Statistics With Reliability, Queuing and Computer Science Applications , 2003, Technometrics.

[31]  Kishor S. Trivedi Probability and Statistics with Reliability, Queuing, and Computer Science Applications , 1984 .

[32]  R. Walker Immunohistochemical markers as predictive tools for breast cancer , 2007, Journal of Clinical Pathology.

[33]  L. Kastl,et al.  miRNA-34a is associated with docetaxel resistance in human breast cancer cells , 2011, Breast Cancer Research and Treatment.

[34]  David A. Landgrebe,et al.  A survey of decision tree classifier methodology , 1991, IEEE Trans. Syst. Man Cybern..

[35]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[36]  An-Qin Zhang,et al.  Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels. , 2012, International journal of oncology.

[37]  Robert Winqvist,et al.  Somatic mutation analysis of MYH11 in breast and prostate cancer , 2008, BMC Cancer.

[38]  J. Johnston,et al.  CENP-V is required for centromere organization, chromosome alignment and cytokinesis , 2008, The EMBO journal.

[39]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Hess,et al.  Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  B. Katzenellenbogen,et al.  Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. , 2008, Cancer research.

[42]  Yuanfang Guan,et al.  A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines. , 2014, Journal of proteomics.

[43]  J. Benítez,et al.  VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. , 2014, Endocrine-related cancer.

[44]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[45]  K. Pantel,et al.  Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells , 2012, Clinical Cancer Research.

[46]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[47]  Yang Li,et al.  Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers , 2015, Scientific Reports.

[48]  Zhonghu Bai,et al.  Breast cancer intrinsic subtype classification, clinical use and future trends. , 2015, American journal of cancer research.

[49]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[50]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[51]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[52]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Pedro M. Domingos,et al.  On the Optimality of the Simple Bayesian Classifier under Zero-One Loss , 1997, Machine Learning.

[54]  Zheng-Zhi Wang,et al.  Center-based nearest neighbor classifier , 2007, Pattern Recognit..

[55]  Seppo Parkkila,et al.  BMC Cancer BioMed Central Research article Carbonic anhydrase IX in oligodendroglial brain tumors , 2008 .

[56]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[57]  M. Takeichi,et al.  Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.

[58]  T. Ohtsuka,et al.  MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. , 2013, Surgery.

[59]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[60]  N. Chandel,et al.  ROS links glucose metabolism to breast cancer stem cell and EMT phenotype. , 2013, Cancer cell.

[61]  J. Gu,et al.  Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma , 2010, Oncogene.

[62]  K. Miyazaki,et al.  Matrilysin (MMP‐7) cleaves C‐type lectin domain family 3 member A (CLEC3A) on tumor cell surface and modulates its cell adhesion activity , 2009, Journal of cellular biochemistry.

[63]  Miae Lee,et al.  CSN5/JAB1 Interacts with the Centromeric Components CENP-T and CENP-W and Regulates Their Proteasome-mediated Degradation* , 2013, The Journal of Biological Chemistry.

[64]  C. Livasy,et al.  Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. , 2007, Experimental and molecular pathology.

[65]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[66]  David Tuck,et al.  A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. , 2011, The Lancet. Oncology.

[67]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[68]  Ping Zhu,et al.  The structural clustering and analysis of metric based on granular space , 2010, Pattern Recognit..

[69]  Miaojian Wan,et al.  A novel onco-miR-365 induces cutaneous squamous cell carcinoma , 2013, Carcinogenesis.